



Scientific

Program

FRIDAY, NOVEMBER 30

5:00-8:00PM **Meeting Registration**

SATURDAY, DECEMBER 1

9:00AM-5:00PM **Exhibit Hall Move-in/Set-up**

12:00-9:00PM **Meeting Registration**

5:00-6:50PM **Fluorescein Angiography & Surgical Case Conference**

6:50-7:00PM **Compounding Drugs - Off Label Drugs - Unapproved Drugs.
The Physician's Right to Choose vs. Wall Street and the Law – Late Edition**
Kirk H. Packo, MD

7:00-10:00PM **Welcome Reception & Dinner**

SUNDAY, DECEMBER 2

6:30-7:30AM **American Retina Foundation – 5K Run/Walk**

7:00-8:00AM **Breakfast & Exhibits**

7:00-5:00PM **Meeting Registration**

7:30-8:00AM **Poster Session 1: AMD (Authors Present)**

8:00-10:00AM **Symposium 1 - AMD I**
Moderators: Albert Augustin, MD & Suber S. Huang, MD, MBA

8:00 **Opening Remarks**
Julia A. Haller, MD (ASRS-President) & David F. Williams, MD, MBA (ASRS Vice-president & Program Chair)

8:05 **Ranibizumab (Lucentis®) for Neovascular Age-Related Macular Degeneration (AMD):
1-Year Results for Fellow Eyes with Neovascular AMD (MARINA, ANCHOR)**
Thomas A. Ciulla, MD

8:10 **Pivotal Phase III Trials of Ranibizumab for Age-related Macular Degeneration:
Overview of 2-Year Safety Results of the MARINA and ANCHOR Studies**
Carl D. Regillo, MD, FACS

8:15 **Time Course of Visual Acuity Changes with Ranibizumab in the 2-Year MARINA Study of Patients
with Neovascular Age-Related Macular Degeneration (AMD)**
Seenu M. Hariprasad, MD

8:20 **Time Course of Visual Acuity Changes with Ranibizumab in the 2-Year ANCHOR Study of
Patients with Neovascular Age-Related Macular Degeneration (AMD)**
Lawrence S. Morse, MD, PhD

8:25 **Discussion**

- 8:30 **ANCHOR—Ranibizumab (LUCENTIS®) vs Photodynamic Therapy in Predominantly Classic Neovascular Age-Related Macular Degeneration: 2-Year Anatomic Outcomes**
Srinivas Reddy Sadda, MD
- 8:35 **Visual Acuity Changes with Ranibizumab: ANCHOR Patients Randomized to Verteporfin Photodynamic Therapy (PDT) who Crossed Over to Ranibizumab in Year 2**
Allen C. Ho, MD
- 8:40 **Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: 24 Month Results from ANCHOR**
Neil M. Bressler, MD
- 8:45 **Long-term (3-Year) Experience with Lucentis® (Ranibizumab) in Patients with Neovascular Age-Related Macular Degeneration In Extension Study 2508**
David S. Boyer, MD
- 8:50 **LUCENTIS® (Ranibizumab) Slows Growth of CNV and CNV Lesion in Patients with Neovascular AMD: 2-Year Angiographic Results of the PIER Study**
David M. Brown, MD, FACS
- 8:55 **Discussion**
- 9:00 **Ranibizumab for Exudative Age-Related Macular Degeneration Following Previous Treatment with Alternative Vascular Endothelial Growth Factor Inhibitors**
Justis P. Ehlers, MD
- 9:05 **Visual Outcomes in Eyes Switched From Pegaptanib to Ranibizumab for Neovascular Age-Related Macular Degeneration**
Zac B. Ravage, MD
- 9:10 **Efficacy of Intravitreal Ranibizumab in Patients with Neovascular Age-related Macular Degeneration Previously Treated with Intravitreal Bevacizumab**
Daniel M. Berinstein, MD
- 9:15 **Discussion**
- 9:20 **Predictive Factors for Outcome After Intravitreal Bevacizumab Treatment of Neovascular Age-Related Macular Degeneration**
Evelyn X. Fu, MD
- 9:25 **Intravitreal Avastin for Large Subfoveal Hemorrhage due to ARMD**
Robert A. Mittra, MD
- 9:30 **Pneumatic Displacement of Submacular Hemorrhage in Exudative AMD Followed by Anti-VEGF Therapy**
Adrian Marcos Lavina, MD
- 9:35 **Discussion**
- 9:40 **Intravitreal Bevacizumab Versus Ranibizumab for Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Case-Control Study**
Adam Martidis, MD
- 9:45 **The LEVEL Study – Maintenance Therapy with Pegaptanib Sodium (Macugen®) in Neovascular Age-Related Macular Degeneration (NV-AMD)**
Thomas R. Friberg, MD

- 9:50 **Intravitreal Bevacizumab for the Treatment of CNV not associated to Age-Related Macular Degeneration. The "PACORES" results**
Virgilio Morales-Canton, MD
- 9:55 **Evolution of the CATT: Fact and Fiction – Late Edition**
Daniel F. Martin, MD
- 10:05-10:30 **Break & Exhibits**
- 10:05-10:30 **Poster Session 4: Retinal Vascular Disease/Complications of Anterior Segment Surgery** (Authors Present)
- 10:30AM-12:45PM **Symposium 2 - Awards & Special Presentations**
Moderators: Julia A. Haller, MD & David F. Williams, MD, MBA
- 10:30 **25th Anniversary Recognition**
- 10:45 **Introduction Pyron Award Winner**
- 10:50 **Pyron Award Lecture – Optical Coherence Tomography (OCT):
The Next Chapter in the Story of a Technology which has Changed the Face of Retinal Practice**
Carmen A. Puliafito, MD, MBA
- 11:20 **Introduction Founders Award Winner**
- 11:25 **Founders' Award Lecture – Livin' la vida "Luvastin"**
Philip J. Rosenfeld, MD, PhD
- 11:55 **The AAO and ASRS: An update regarding topics of mutual interest**
C. Pat Wilkinson, MD (President, AAO)
- 12:05 **American Retina Foundation Presentation**
Roy A. Levit, MD
- 12:10 **YPS Crystal Apple Award Presentation to Michael T. Trese, MD**
Robert Kwun, MD & Andrew Lauer, MD
- 12:12 **PAT Survey Award Presentation**
Robert A. Mittra, MD
- 12:15 **ASRS Business Meeting**
- 12:45 **Young Physicians' Section – Lunch**
- 12:45 **Lunch** (On Your Own)
- 2:00-4:35 **Symposium 3 - AMD II**
Moderators: Antonio Capone, MD & Seenu M. Hariprasad, MD
- 2:00 **Combined Photodynamic Therapy with Intravitreal Dexamethasone for the Treatment of Neovascular Age-Related Macular Degeneration**
Subhransu K. Ray, MD, PhD
- 2:05 **Combination Bevacizumab and Verteporfin in Neovascular Age-Related Macular Degeneration: 6-Month Results of a Randomized Clinical Trial**
Joel Pearlman, MD, PhD
- 2:10 **Reduced Fluence Photodynamic Therapy and Bevacizumab for Exudative Age-Related Macular Degeneration - A Comparison with Anti-VEGF Monotherapy**
Edwin H. Ryan, MD

- 2:15 **A Randomized Double-Masked Study Comparing Lucentis Monotherapy and PDT Combined with Lucentis Therapy in Patients with CNV Secondary to AMD**
Christian Prunte, MD
- 2:20 **Outcomes of FOCUS Patients with Previously Untreated Subfoveal Wet Age-related Macular Degeneration Receiving LUCENTIS® + Verteporfin PDT or PDT alone**
Rajendra S. Apte, MD, PhD
- 2:25 **Discussion**
- 2:30 **Triple Therapy for the Treatment of Wet AMD**
Albert J. Augustin, MD
- 2:35 **Quadruple Therapy for AMD with Significantly Reduced Retreatment Rates at 14 Months. Vitrectomy may help Angiogenic Factors Diffuse from the Retina**
Frank HJ Koch, MD
- 2:40 **Endophthalmitis Rate and Utility of Post-Injection Telephone Contact and Clinical Examination in detecting Endophthalmitis after Ranibizumab Injection**
Philip J. Ferrone, MD
- 2:45 **The Incidence of Retinal Pigment Epithelial Tears in Eyes Treated with Ranibizumab**
Bradley T. Smith, MD
- 2:50 **Discussion**
- 2:55 **Retinal Pigment Epithelial Tears after Intravitreal Bevacizumab Injection for Exudative Age-Related Macular Degeneration**
Sunir J. Garg, MD
- 3:00 **Risk of Myocardial Infarction and Cerebrovascular Accident in Neovascular Age-Related Macular Degeneration Patients and Controls**
Diana V. Do, MD
- 3:05 **Annual Rates of Arterial Thromboembolic Events in Medicare Neovascular Age-Related Macular Degeneration Patients with Comorbidities**
Anne E. Fung, MD
- 3:10 **Discussion**
- 3:15 **Randomized Comparison Study of Safety and Bioactivity of Two Dose Levels of ITV VEGF Trap in Neovascular AMD: Primary Endpoint and Long-Term Follow Up**
Quan Dong Nguyen, MD, MSc
- 3:20 **A Phase 2, Randomized, Controlled Dose-and Interval-Ranging Study of Intravitreal VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration: Primary Endpoint and Extended Follow Up Results**
Jeffrey S. Heier, MD
- 3:25 **A Phase 2, Randomized, Controlled Dose-and Interval-Ranging Study of Intravitreal VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration: OCT and Fluorescein Angiographic Outcomes**
Jason S. Slakter, MD
- 3:30 **Discussion**

- 3:35 **Role of Fluorescein Angiography and OCT as Guidelines to Determine Continuation of Treatment in Patients with Neovascular AMD on anti-VEGF Therapy**
Christopher Chambers, MD
- 3:40 **Effect on High Contrast Discriminated Target Central Fields of Avastin Monotherapy for CNVM due to AMD**
Stephen H. Sinclair, MD
- 3:45 **The Relationship between the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) and Reading Speed and Restricted Activity Days**
Michael J. Cooney, MD
- 3:50 **The NEI VFQ-25 Results of the MARINA Trial: What is clinically meaningful to patients and physicians?**
Gregg T. Kokame, MD
- 3:55 **Discussion**
- 4:00 **ICG-directed PDT for Anti-VEGF Therapy Failures in Neovascular AMD**
Scott W. Cousins, MD
- 4:05 **Intravitreal Bevasiranib in Exudative Age-related Macular Degeneration or Diabetic Macular Edema**
Lawrence J. Singerman, MD
- 4:10 **Combined Safety of Focal Epiretinal Brachytherapy in Two Feasibility Studies of Subfoveal Choroidal Neovascularization (CNV) Secondary to AMD**
Carl C. Awh, MD
- 4:15 **The Retinologists Evaluating Triamcinolone in Neovascular AMD Trial (The Canadian RETINA study) – 1-year study results**
David A.L. Maberley, MD, FRCS(C)
- 4:20 **Long-Term Visual Acuity, Safety, and Patient Management Factors of a Telescope Prosthesis for End-Stage AMD (IMT002 Study)**
Henry L. Hudson, MD, FACS
- 4:25 **Immune-based Systemic Therapy with Copaxone for Dry Age-related Macular Degeneration (AMD)**
Ayala Pollack, MD
- 4:30 **Discussion**
- 4:35 **Adjourn**
- 5:00-6:30 **Women in Retina Symposium & Reception**
- 6:30-10:30 **Free evening** (Transportation to local restaurants provided.)

6:45-7:45AM

Breakfast with the Masters

Moderator: Stewart A. Daniels, MD

7:00-8:00AM

Breakfast & Exhibits

7:00AM-1:00PM

Meeting Registration

8:00-10:00AM

Symposium 4: Retinal Vascular Disease/Complications of Anterior Segment Surgery

Moderators: Robert L. Avery, MD & Gregg T. Kokame, MD

8:00

Safety and Efficacy of Pegaptanib Sodium in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion

John A. Wells, MD, FACS

8:05

Pegaptanib for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: Interim Results of An Open-Label Study

John J. Wroblewski, MD

8:10

Intravitreal Bevacizumab for Treatment of Macular Edema Associated with Central Retinal Vein Occlusion

Newman J. Sund, MD, PhD

8:15

Impact of the Interval between Symptom Onset and Intravitreal Bevacizumab Injection for Treatment of Macular Edema from Retinal Vein Occlusion

Chirag Patel, MD

8:20

One year safety and efficacy of Intravitreal Bevacizumab (Avastin) for Macular Edema Secondary to Central and Branch Retinal Vein Occlusions

Ninel Z. Gregori, MD

8:25

Intravitreal Ranibizumab Treatment in Patients with Macular Edema Associated with Perfused Central Retinal Vein Occlusions

Dante J. Pieramici, MD

8:30

Discussion

8:40

Intraocular Bevacizumab Improves Visual Outcomes in Neovascular Glaucoma

Jorge I. Calzada, MD

8:45

Treatment of Neovascular Glaucoma with and without Avastin

Rohit Ross Lakhanpal, MD

8:50

Discussion

8:55

Long-Term Outcomes of Vitrectomy and Posterior Hyaloidal Separation for Macular Edema Secondary to Retinal Vein Occlusions

Michael M. Lai, MD, PhD

9:00

Stable Long Term Visual Recovery in Central and Branch Retinal Vein Occlusion after Revascularization by Anastomotic Decompression (RAD)

Calvin A. Grant, MD

9:05

Discussion

9:10

In-office Pharmacologic Vitreolysis with Intravitreal Autologous Plasmin Enzyme Plus Intravitreal Bevacizumab to Treat Refractory Macular Edema

Tarek S. Hassan, MD

- 9:15 **Intravitreal Anti-VEGF Therapy (Avastin) in Treatment of Radiation Retinopathy and Optic Neuropathy**
Paul T. Finger, MD, FACS
- 9:20 **Visual and Anatomic Outcomes of Idiopathic Polypoidal Choroidal Vasculopathy in Patients of Caribbean Descent**
Geeta A. Lalwani, MD
- 9:25 **Neurosensory Retinal Detachments as a Sequelae of Malignant Hypertension**
Parin S. Gohel, MD
- 9:30 **Discussion**
- 9:35 **Incidence of Cystoid Macular Edema after Pars Plana Lensectomy and Vitrectomy for Complicated Cataract Surgery and the Perioperative Steroid Effect**
Yevgeniy Shildkrot, MD
- 9:40 **Primary Intravitreal Bevacizumab (Avastin®) for the Management of Pseudophakic Cystoid Macular Edema**
Maurício Maia, MD
- 9:45 **Case Series for Management Of Dislocated All Acrylic (1-Piece AcrySof) Posterior Chamber Implants With Long Term Follow-Up**
Clement K. Chan, MD
- 9:50 **Discussion**
- 10:00-10:30 **Break & Exhibits**
- 10:00-10:30 **Poster Session 5: Diabetic Retinopathy/Inflammatory and Infectious Diseases** (Authors Present)
- 10:30AM-12:50PM **Symposium 5: Diabetic Retinopathy/Inflammatory and Infectious Diseases**
Moderators: Susan B. Bressler, MD & Glenn J. Jaffe, MD
- 10:30 **Comparison of Optical Coherence Tomography (OCT) and Fundus Photographic Assessments of Diabetic Macular Edema**
Susan B. Bressler, MD
- 10:35 **A Genome-Wide Linkage Scan for Diabetic Retinopathy: Results of the Family Investigation of Nephropathy & Diabetes Study in a Multi-Ethnic Cohort**
Emily Y. Chew, MD
- 10:40 **Lucentis in the Treatment of Macular Edema (LIME):
A Phase II Trial of Ranibizumab Compared with Focal Laser Treatment in Patients with DME**
Roy A. Goodart, MD
- 10:45 **12-month Phase I Results with the I-vation™ TA Intravitreal Implant for treatment of DME**
Pravin U. Dugel, MD
- 10:50 **Pre-treatment Variables Associated With Response to a Fluocinolone Acetonide Implant for Diabetic Macular Edema**
Saad Ahmad, MD
- 10:55 **Selective Retinal Laser for the Treatment of Diabetic Macular Edema**
Umit Ubeyt Inan, MD
- 11:00 **Discussion**

- 11:08 **Transconjunctival 25-Gauge Vitrectomy for One Hundred Consecutive Diabetic Traction Retinal Detachments: Visual And Anatomic Outcome**
John O. Mason, MD
- 11:13 **Intravitreal Bevacizumab in the Surgical Treatment of Proliferative Diabetic Retinopathy**
Robert L. Avery, MD
- 11:18 **Tractional Retinal Detachment following Intravitreal Bevacizumab (Avastin®) in Patients with Severe Proliferative Diabetic Retinopathy**
J. Fernando Arevalo, MD, FACS
- 11:23 **Panretinal Photocoagulation Combined with Avastin in the Treatment of Proliferative Diabetic Retinopathy**
Murat Oncel, MD
- 11:28 **Pegaptanib Sodium (Macugen®) versus Panretinal Photocoagulation in the Treatment of Proliferative Diabetic Retinopathy**
Victor Hugo Gonzalez, MD
- 11:33 **Single Session PASCAL Photocoagulation for Proliferative Diabetic Retinopathy**
Anurag Gupta, MD
- 11:38 **Discussion**
- 11:45 **Intravitreal Bevacizumab in patients with Choroidal Neovascularization associated with POHS and Inflammatory Choroiditis treated longer than one year**
Sundeev Dev, MD
- 11:50 **Subfoveal and Juxtafoveal Choroidal Neovascularization Secondary to Ocular Histoplasmosis Syndrome Treated with Intravitreal Bevacizumab (Avastin)**
David G. Dodwell, MD
- 11:55 **Discussion**
- 12:00 **Secondary Ocular Hypertension and Noninfectious Endophthalmitis Following Intravitreal Triamcinolone Injection**
Marcio B. Nehemy, MD, PhD
- 12:05 **Rate of Endophthalmitis following Intravitreal Injections in the Anti-VEGF Era**
Andrew A. Moshfeghi, MD
- 12:10 **The Risk of Endophthalmitis Following Intravitreal Triamcinolone Injection in the DRCR.net and SCORE Clinical Trials**
Abdhis R. Bhavsar, MD
- 12:15 **Endophthalmitis after Small-Gauge Pars Plana Vitrectomy**
Harry W. Flynn, MD
- 12:20 **Discussion**
- 12:25 **Outcomes of Pars Plana Vitrectomy in the Management of Eyes with Coexisting Noninfectious Uveitis**
ONeil Michel Biscette, MD, MS
- 12:30 **Toxoplasmosis induced Posterior Uveitis; a surgical cure?**
Thierry C. Verstraeten, MD

- 12:35 **Combined Fluocinolone Acetonide Sustained Drug Delivery System Implantation and Phacoemulsification/Intraocular Lens Implantation for Severe Uveitis**
Glenn J. Jaffe, MD
- 12:40 **Patterns of Fundus Autofluorescence in Posterior Uveitic Syndromes**
Steven Yeh, MD
- 12:45 **Discussion**
- 12:50 **Adjourn**
- 12:50-6:00PM **Free Afternoon/Golf Tournament/Tennis Tournament**
- 6:00-10:00PM **Evening at Empire Polo Club**

TUESDAY, DECEMBER 4

- 7:00-8:00AM **Breakfast & Exhibits**
- 7:00AM-5:30PM **Meeting Registration**
- 7:30-8:00AM **Poster Session 6: Pharmacology/Imaging - Digital - Angiography** (Authors Present)
- 8:00-10:00AM **Symposium 6: Pharmacology/Imaging - Digital - Angiography**
Moderators: Anat Loewenstein, MD & Polly Quiram, MD
- 8:00 **A Comparison of the Safety Profile of Bevacizumab and Ranibizumab on Retinal Cells in Culture**
Aneesh Neekhra, MD
- 8:05 **Comparative Study of the Safety Profile of Various Combinations of Anti-VEGF and Steroid Therapies on Retinal Neurosensory Cells in Culture**
Baruch D. Kuppermann, MD, PhD
- 8:10 **Comparison of the Pharmacokinetics of Intravitreal Ranibizumab and Intravitreal Bevacizumab**
Sophie J. Bakri, MD
- 8:15 **Ranibizumab and Bevacizumab- Pharmacokinetic and Penetration Studies**
Anat Loewenstein, MD
- 8:20 **Discussion**
- 8:25 **Pharmacokinetic Modeling to Improve the Design of Intravitreal Corticosteroid Implants for Treating Macular Edema**
Susan S. Lee, MS
- 8:30 **Dexamethasone Posterior Segment Drug Delivery System: Pharmacokinetics in Vitrectomized and Non-vitrectomized Eyes**
Devin Welty, PhD
- 8:35 **Long Term Incidence and Timing of Intraocular Hypertension Following Intravitreal Triamcinolone Acetonide Injection**
Daniel B. Roth, MD
- 8:40 **Acute, Severe, Elevation of Intraocular Pressure after Injection of Intravitreal Triamcinolone: Analysis of Crystal Size**
Lawrence S. Halperin, MD
- 8:45 **Discussion**

- 8:50 **Enzymatic Induction of a Posterior Vitreous Detachment Affects VEGF Levels in Animal Models**
Polly A. Quiram, MD, PhD
- 8:55 **MIVI-2T Trial: A Randomized, Double-masked, Clinical Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Vitreomacular Traction**
Peter Stalmans, MD, PhD
- 9:00 **A New Posterior Segment Drug Delivery System using Thermo-Responsive Hydrogels**
William F. Mieler, MD
- 9:05 **Discussion**
- 9:10 **Ultra-widefield Fluorescein Angiography for Detection of Peripheral Retinal Pathology**
Scott C. N. Oliver, MD
- 9:15 **Characteristics of Neovascularization in Eyes with Macular Telangiectasia**
Robert P. Murphy, MD
- 9:20 **Discussion**
- 9:25 **Initial Effect of Anti-VEGF-therapy on Different Retinal Compartments**
Christian Ahlers, MD
- 9:30 **High-Resolution Ultrasonography Examination of Patients Who Have Undergone Multiple Intravitreal Injections - Interim Study Results**
Ingrid E. Zimmer-Galler, MD
- 9:35 **Discussion**
- 9:40 **Comparison of Clinical Findings from High Resolution Three Dimensional Fourier Domain and Conventional Time Domain OCT**
Alexander C. Walsh, MD
- 9:45 **Maculopathy Diagnosed with High Resolution Fourier-domain Optical Coherence Tomography among Subjects with Previously Unexplained Visual Loss**
Susanna S. Park, MD, PhD
- 9:50 **Discussion**
- 10:00-10:30 **Break & Exhibits**
- 10:00-10:30 **Poster Session 7: Instrumentation and Devices/Hereditary Retinal Disease & Genetics/Ocular Oncology/Socioeconomics (Authors Present)**
- 10:30am-1:00PM **Symposium 7: Instrumentation and Devices/Hereditary Retinal Disease & Genetics/Ocular Oncology/Socioeconomics**
Moderators: Clement K. Chan, MD & John T. Thompson, MD
- 10:30 **Vision in Blind Subjects Implanted with Second Sight Medical Products Epiretinal Prosthesis**
Mark S. Humayun, MD, PhD
- 10:35 **Surgical Methods and Outcomes of the Second Generation Intraocular Retinal Prosthesis implant**
Rajat Agrawal, MD
- 10:40 **Discussion**

- 10:45 **Duty Cycle Control During Pars Plana Vitrectomy: An Evaluation of a New Vitrectomy System with Slow Motion Videography**
Kirk H. Packo, MD
- 10:50 **Laboratory Evaluation of Pulsatile Changes in IOP and Infusion Flow Caused by Opening and Closing of the Cutter Port**
Steve T. Charles, MD
- 10:55 **Vitreous Cutter Performance Evaluated: 20, 23, 25 Gauge Comparison of Characteristics**
Jean Pierre Hubschman, MD
- 11:00 **Performance Analysis of a Second Generation Pneumatic Cutter Engineered to Sustain a High Duty Cycle at High Cutting Rates: MID Labs AVE**
Lawrence P. Chong, MD
- 11:05 **Discussion**
- 11:10 **Pulsed Micro-Injector for Intravitreal Drug Delivery**
Mark S. Blumenkranz, MD
- 11:15 **Premium IOLs and Retina Viewing**
David R. Chow, MD, FRCS(C)
- 11:20 **Discussion**
- 11:25 **Factor H Polymorphism in Pathological Ocular Neovascularization**
Suber S. Huang, MD, MBA
- 11:30 **Phase II/III Studies of Encapsulated CNTF Secreting Cell Implant (NT-501) in Patients with Dry AMD or Retinitis Pigmentosa**
Weng Tao, MD, PhD
- 11:35 **Discussion**
- 11:40 **Transscleral Fine Needle Aspiration Biopsy of Macular Choroidal Melanoma**
Tara A. Young, MD, PhD
- 11:45 **Primary Transpupillary Thermotherapy for Small Choroidal Melanomas**
Jennifer I. Lim, MD
- 11:50 **Juxtapapillary Choroidal Malignant Melanoma: Custom Notched Plaque 125Iodine Brachytherapy: a Completed 5 year Pilot Clinical Trial**
Timothy G. Murray, MD, MBA
- 11:55 **Discussion**
- 12:00PM **The ASRS Strategic Planning: the Practice Management Project**
Julia A. Haller, MD
- 12:05 **Discussion**
- 12:15 **A Time Motion Study of Common Vitreoretinal Procedures**
Paul E. Tornambe, MD

12:20	Bevacizumab vs. Ranibizumab: The Impact of Off-label Drug Use on Innovation in Ophthalmology David F. Williams, MD, MBA
12:25	The times they are a changing George A. Williams, MD
12:30	Discussion
12:40	The Democratic Congress and New Valuation of Surgical Services: Who Would Have Thunk it William L. Rich, III, MD, FACS - AAO Medical Director of Health Policy
12:50	Discussion
1:00-2:00PM	Lunch (on your own)
2:00-6:00	Instructional Courses (Included in Registration Fee; Sign-up will be on-site.)
	AIDS and the Eye Mallika Goyal, MD, Alay S. Banker, MD, John H. Kempen, MD, PhD, Narsing A. Rao, MD
	Transconjunctival Techniques for 25G Surgery John O. Mason, MD, Milton F. White, Jr., MD, Richard M. Feist, MD, Michael A. Albert, Jr., MD
	Grand Rounds with WinR Women in Retina
	The Art of PowerPoint & Photoshop Kirk H. Packo, MD
	Margaritas with the Masters Paul E. Tornambe, MD
	Controversies in Vitreoretinal Surgery – The Silver Anniversary Debates Carl C. Awh, MD, David R. Chow, MD, FRCS(C), Tarek S. Hassan, MD, Philip J. Ferrone, MD, Allen C. Ho, MD, Carl D. Regillo, MD, FACS, Steven D. Schwartz, MD, Stanislao Rizzo, MD
	ILM Peeling – 20 Years Experience Didier Ducournau, MD, Yvette Ducournau, MD
	Pars Plana Vitrectomy Vicente Martinez-Castillo, MD, Anna Boixadera, MD, José García-Arumí, MD
	History of Retina Kirk H. Packo, MD
	The Business of Retina – Late Edition George Eliades
	Principles & Practice of Wet AMD Treatment Nabil M. Jabbour, MD, J. Vernon Odom, PhD
6:00	Adjourn
6:30PM-Midnight	Cocktails & Gala

- 8:00-8:00AM **Breakfast & Exhibits**
- 7:00AM-12:00PM **Meeting Registration**
- 7:30-8:00AM **Poster Session 8: Surgical Techniques and Maneuvers/Macular Holes/Macular Puckers & Poster Session 9: Retinal Detachment/Pediatric Retina/Trauma** (Authors Present)
- 8:00AM-10:00AM **Symposium 8: Surgical Techniques and Maneuvers/Macular Holes/Macular Puckers**
Moderators: Eugene de Juan, Jr., MD & Marcio B. Nehemy, MD
- 8:00 **A Study of Surgical Methodology to Reduce Vitreous Incarceration to 25-Gauge Sutureless Sclerotomies**
Rizwan Bhatti, MD (*Winner of B&L Retina Fellows' Forum 2007*)
- 8:05 **Modified 25-Gauge Sclerotomy**
Flavio A. Rezende, MD, PhD
- 8:10 **23-Gauge Vitrectomy as an Effective and Safe Alternative for Sutureless Vitreous Surgery**
Keith A. Warren, MD
- 8:15 **"Biplanar 5/30 Insertion Technique" Produces Improved Wound Construction for 23G One-Step Entry Vitrectomy System**
John S. Pollack, MD
- 8:20 **23-Gauge One-Step Vitrectomy: the extreme end of wound construction**
Stanislao Rizzo, MD
- 8:25 **Discussion**
- 8:35 **Comparative Study on Surgical Outcomes and Complications of 23-Gauge versus 20-Gauge Pars Plana Vitrectomy**
Ching J. Chen, MD
- 8:40 **Further Experience with 20-Gauge Transconjunctival Sutureless Vitrectomy**
Daniel G. Polya, MBBS, MPH
- 8:45 **Discussion**
- 8:50 **Long-term Results of Scleral-sutured Posterior Chamber Lens Implantation Combined with Pars Plana Vitrectomy for Aphakic Correction**
Rishi P. Singh, MD
- 8:55 **Successful Management of Posteriorly Dislocated PC- IOLs with the Twenty-Five Gauge Vitrectomy and Modified McCannel Iris-Suture Technique**
Kenneth Wald, MD
- 9:00 **Discussion**
- 9:05 **Supra-Choroidal Drug Delivery**
Tom S. Chang, MD
- 9:10 **Complications of Intravitreal Drug Injections**
Nader Moinfar, MD
- 9:15 **Discussion**
- 9:20 **Autologous Blood for Visualization during ILM Peeling**
Colin A. McCannel, MD
- 9:25 **Macular Hole Formation Visualized with Spectral Optical Coherence Tomography**
Jerzy Nawrocki, MD, PhD

- 9:30 **Spectral Optical Coherence Tomography of Surgically Closed Macular Holes**
Zofia Michalewska, MD
- 9:35 **Vitrectomy for Epiretinal Membranes Associated with Lamellar Macular Holes**
John T. Thompson, MD
- 9:40 **Cystoid Macular Edema after 25-g Vitrectomy for the Treatment of Epiretinal Membranes:
an emerging complication**
Federica Genovesi-Ebert, MD, PhD
- 9:45 **Discussion**
- 10:00-10:30 **Break & Exhibits**
- 10:30-11:50 **Symposium 9: Retinal Detachment/Pediatric Retina/Trauma**
Moderators: Tarek S. Hassan, MD & John S. Pollack, MD
- 10:30 **25-Gauge Transconjunctival Sutureless Vitrectomy versus 20-Gauge Vitrectomy for the Repair
of Primary Rhegmatogenous Retinal Detachment**
Manfred A. von Fricken, MD
- 10:35 **Vitrectomy vs. Scleral Buckle Procedure in 252 Rhegmatogenous Retinal Detachment Cases**
Gerhard F. Kieselbach, MD
- 10:40 **Recurrent Retinal Detachment after Primary Retinal Detachment Repair with Scleral Buckle or
Vitrectomy**
George J. Ko, MD
- 10:45 **Primary Proliferative Vitreoretinopathy (PVR): Characteristics and Outcomes of a Large Patient
Series from Colombia, South America**
Carlos Alberto Abdala, MD
- 10:50 **Pediatric Rhegmatogenous Retinal Detachment: Clinical Features and Surgical Outcomes**
Christine R. Gonzales, MD
- 10:55 **Discussion**
- 11:05 **ROP Retinal Detachment: Vitreous Biochemistry in Stage 4 and 5 Detachments**
Kimberly A. Drenser, MD
- 11:10 **Role of Antiangiogenic Therapy with Bevacizumab in Retinopathy of Prematurity**
Maria Ana Martinez-Castellanos, MD
- 11:15 **18-Month Experience with Telemedicine Screening for ROP**
Darius M. Moshfeghi, MD
- 11:20 **Discussion**
- 11:30 **Combat Ocular Trauma during Operations Iraqi and Enduring Freedom**
Eric D. Weichel, MD
- 11:35 **Visual Outcomes of Perforating Ocular Injuries from Combat Ocular Trauma During Operation
Iraqi Freedom from March 2003 through October 2006**
Marcus H. Colyer, MD
- 11:40 **Discussion**
- 11:50 **Meeting Adjourns**